1. ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018: 1-64. In press.
2. Dormandy J, Nehler M, Harris K, Fowkes F on behalf of the TASC II Working Group Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg, 2007, 33(Suppl 1).
3. Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J, 1982, 104: 66-72.
4. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology, 1983, 34: 40-45.
5. Tarichko Yu.V., Zudin A.M., Uchkin I.G., Talov N.A., Khmyrova A.V. Opyt primeneniya pentoksifillina prolongirovannogo deistviya v kompleksnom lechenii troficheskikh defektov tkanei pri kriticheskoi ishemii nizhnikh konechnostei. Farmateka, 2011, 10: 66-69./ Tarichko YuV, Zudin AM, Uchkin IG, Talov NA, Khmyrova AV. Experience in using sustained action pentoxifylline in the combination treatment of trophic tissue defects in criticallowerlimb ischemia. Farmateka, 2011, 10: 66-69.